PICSAR (P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA)

In females with RA, PICSAR lncRNA levels showed a positive correlation with ACR scores and a negative correlation with age. Interpretation & conclusions PICSAR lncRNA is implicated in RA pathogenesis and may serve as a potential non-invasive diagnostic biomarker for RA.

RAPGEFL1 regulates the Rap signaling pathway, controlling adhesion, migration, polarity, and metabolism to maintain cellular and tissue homeostasis. Its dysregulation is linked to various diseases, highlighting its potential as a therapeutic target.

Our findings indicated that LINC00162 silencing, in combination with sorafenib, reduced the expression of MAPK, KRAS, and RAF genes. From our findings, we can conclude that LINC00162 silencing, both individually and combined with sorafenib, reduced the progression and viability of thyroid cancer cells through modulating genes involved in key pathways and could be considered a new therapeutic approach for the treatment of papillary thyroid cancer (PTC).

P=N/A, N=223, Enrolling by invitation, Sahlgrenska University Hospital, Sweden | Initiation date: May 2024 --> Aug 2024

P=N/A, N=223, Enrolling by invitation, Sahlgrenska University Hospital, Sweden

In conclusion, this systematic review showed that NMSC-derived EVs display promise as therapeutic targets and diagnostic biomarkers. Further research is imperative to fully comprehend EV mechanisms and explore their potential in cancer diagnosis and treatment.

Moreover, 29 drugs such as sorafenib, dasatinib and paclitaxel were screened for high-risk HCC patients to improve their prognosis. Our prognostic cuproptosis-related lncRNA signature was accurate and effective for predicting the prognosis of HCC. The immunotherapy was unsuitable for high-risk HCC patients with this signature.

7 glucose metabolism-related lncRNAs risk score model had a high prognostic value in breast cancer. PICSAR, LINC00839, AP001505.1, LINC00393 were risk factors. AP001505.1 expression was increased in most triple-negative breast cancer cells treated with high glucose, which may also take part in breast cancer progression and potential therapeutic targets.

Moreover, the potential drugs that HCC might be sensitive to were screened by drug sensitivity profiling analysis. Taken together, our findings provided important information for the prediction of the prognosis of HCC patients and the development of personalized targeted therapy.